Vitamin K - Phytomenadione

FORM

Konakion MM Paediatric 2mg/0.2ml– solution for IM or IV use.
Caution: adult strength injection also available

INDICATION

1. Prevention of haemorrhagic disease of the newborn. See protocol for full details.
2. Use of intravenous Vitamin K where clinically indicated

DOSE RANGE

1. Prevention of haemorrhagic disease of the newborn. (Patient Group Direction)

AGE	DOSE	FREQUENCY	ROUTE
Preterm (< 36weeks)	0.5mg (0.05ml)	Single dose *	IM
Term (≥ 36 weeks)	1mg (0.1ml)	Single dose *	IM

* **GIVE SOON AFTER BIRTH.** **Use Konakion MM Paediatric 2mg in 0.2ml strength.**

Mothers who refuse to allow the IM dose of Vitamin K to be given to the baby, should be offered the oral Vitamin K regime see **GG&C Neonatal Guideline – Vitamin K Prophylaxis for Neonates**

2. Use of intravenous Vitamin K where clinically indicated

AGE	DOSE	FREQUENCY	ROUTE
Birth to 6months	1mg	As required depending on clinical picture and coagulation status	IV* over 5 to 10minutes

RECONSTITUTION

Not required

DILUTION

* Konakion MM Paediatric 2mg/0.2ml to be used - Dilute with Glucose 5%. The infusion must be freshly prepared prior to use.

Konakion MM Paediatric 2mg/0.2ml	0.3ml
Glucose 5%	up to 3ml total volume

Gives 1mg/ml solution.

METHOD OF ADMINISTRATION

The line should be flushed with IV glucose 5% before and after administration.

COMPATIBILITY

Solution compatibility	Glucose 5%
Solution incompatibility	Sodium Chloride solutions
IV Line compatibility	
IV Line incompatibility	

THIS LIST IS NOT EXHAUSTIVE PLEASE CONTACT PHARMACY FOR FURTHER INFORMATION ON COMPATIBILITY WITH ANY MEDICINES NOT INCLUDED

CAUTIONS, CONTRA-INDICATIONS AND SIDE EFFECTS
- See Summary of Product Characteristics and most recent edition of BNF for Children (links below)

FURTHER INFORMATION

- Care required over selection of the correct product as administration of the wrong product can lead to anaphylactic shock.
- IV injection may cause peripheral vascular collapse, cyanosis, sweating and flushing if given too rapidly.
- Parenteral administration to premature babies weighing < 2.5Kg may increase the risk for the development of kernicterus.

PH 5.3 – 6.6

LICENSED STATUS

Konakion MM Paediatric - licensed for:

IM and oral use for prophylaxis of haemorrhagic disease of the newborn in healthy neonates > or = 36 weeks gestation.

IM and IV prophylaxis of haemorrhagic disease of the newborn < 36 weeks or term neonates at special risk (off label at dose above). Licensed IV for treatment of haemorrhagic disease of the newborn.

Dose in monograph is off label

LINKS BNF for Children: / Electronic Medicines Compendium

APPLICABLE POLICIES West of Scotland Neonatal Guidelines:

Consult local policy if applicable

Document Number:	001	Supersedes:	Nil
Prepared by:	WoS Neo pharm group	Checked by	Hazel Fisher
Date prepared	June 2016	Date updated	
Updated by		Review Date	June 2019

Administer reconstituted solutions immediately.
All vials, ampoules and infusion bags are for single use only unless otherwise stated.
Dose may vary depending on indication, age, renal function, hepatic function, and concomitant medications.
This monograph should be used in conjunction with the package insert, BNF for Children, and Summary of Product Characteristics. For further advice contact your clinical pharmacist or pharmacy department.